The treatment of medulloblastoma – the most common malignant pediatric brain tumor – has evolved tremendously over the past several decades. At St. Jude, an innovative clinical trial, SJiMB21, is further advancing treatment by identifying therapies that best improve outcomes and quality of life for infants and young children newly diagnosed with medulloblastoma.

By using molecular information to classify different subtypes of the brain tumor, investigators design treatments based on how the tumor might respond. SJiMB21 is the first brain-tumor trial to adopt treatment approaches based on tumor molecular classification. But the effort to improve outcomes extends beyond a more precise treatment of the tumor itself.

The brain-tumor trial also looks to address long-term side effects and improve quality of life for infants and young children with medulloblastoma. It is the first to assess neurocognitive and hearing function and develop interventions that promote healthy childhood development and improve adult life.

Learn more about the SJiMB21 clinical trial and its aim to treat infants with medulloblastoma here: stjude.org/SJiMB21

Follow @StJudeResearch across social media to explore St. Jude science and clinical care.

Twitter: https://bit.ly/StJude-Twitter
Facebook: https://bit.ly/StJude-Facebook
Instagram: https://bit.ly/StJude-Instagram
LinkedIn: https://bit.ly/StJude-LinkedIn
Mastodon: https://bit.ly/StJude-Mastodon
Threads: https://www.threads.net/@stjuderesearch

#Medulloblastoma #BrainTumor #Treatment #Prognosis #Pathology #Histology #Radiotherapy #ChildhoodCancer #Infant #EarlyChildhood #ChildPsychology